Neurocrine Biosciences | NBIX - Betriebsergebnis

Aktienkurs
128.89
Täglich Wechseln
-2.75 -2.09%
Monatlich
-0.50%
Jährlich
41.84%
Q2 Prognose
125.37




Betriebsergebnis Veränderung Datum
AbbVie USD 5.81B 1.23B 2025-12
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
ALKERMES USD -10.95M 100.03M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amgen USD 3.96B 464M 2025-12
Biogen USD 659.6M 192.2M 2025-09
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Cytokinetics USD -178.37M 11.61M 2025-12
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Exelixis USD 235.91M 20.45M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Incyte USD 383.88M 47.43M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
Prothena USD -27.21M 12.55M 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Repligen USD 19.97M 7.29M 2025-12
Rigel Pharmaceuticals USD 14.06M 13.61M 2024-09
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Teva Pharmaceutical Industries USD 487M 581M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12
Xoma USD -15.64M 5.56M 2024-09